Indication
Endometrial Cancer Stage I
5 clinical trials
6 products
1 drug
Clinical trial
A Phase 2b, Open-label, Single Arm, Multicentre, Pilot Study of the Efficacy, Safety and Tolerability of Dostarlimab in Women With Early-stage MMR Deficient Endometrioid Endometrial Adenocarcinoma.Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
Dostarlimab-GxlyClinical trial
Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial CancerStatus: Recruiting, Estimated PCD: 2025-03-10
Product
Megestrol AcetateProduct
Medroxyprogesterone AcetateProduct
TriprorelinProduct
LetrozoleClinical trial
Randomized Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Therapy for Women With Early Stage Endometrioid AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31
Product
Chemoradiation therapyClinical trial
Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial CancerStatus: Recruiting, Estimated PCD: 2023-12-31
Drug
MetforminClinical trial
Prospective Clinical Study of Fertility-sparing Treatment With a Membrane-inhibiting Formula Combined With Oral Progestins for Endometrial Carcinoma and Hyperplasia in Childbearing-age WomenStatus: Recruiting, Estimated PCD: 2025-07-31